10:31:50 Europe / Stockholm
Svenska | English

Lumito

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-20 Bokslutskommuniké 2024
2024-10-31 Kvartalsrapport 2024-Q3
2024-08-23 Kvartalsrapport 2024-Q2
2024-05-08 Ordinarie utdelning LUMITO 0.00 SEK
2024-05-07 Kvartalsrapport 2024-Q1
2024-05-07 Årsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2023-10-31 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-05-26 Ordinarie utdelning LUMITO 0.00 SEK
2023-05-25 Årsstämma 2023
2023-05-03 Kvartalsrapport 2023-Q1
2023-02-23 Bokslutskommuniké 2022
2022-11-02 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-30 Ordinarie utdelning LUMITO 0.00 SEK
2022-05-27 Årsstämma 2022
2022-05-06 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-24 Extra Bolagsstämma 2021
2021-10-20 Kvartalsrapport 2021-Q3
2021-08-18 Kvartalsrapport 2021-Q2
2021-05-28 Ordinarie utdelning LUMITO 0.00 SEK
2021-05-27 Årsstämma 2021
2021-04-28 Kvartalsrapport 2021-Q1
2021-02-17 Bokslutskommuniké 2020
2020-11-03 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-28 Ordinarie utdelning LUMITO 0.00 SEK
2020-05-27 Årsstämma 2020
2020-04-28 Kvartalsrapport 2020-Q1
2020-02-17 Bokslutskommuniké 2019
2019-10-31 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-06-04 Årsstämma 2019
2019-05-23 Ordinarie utdelning LUMITO 0.00 SEK
2019-04-30 Kvartalsrapport 2019-Q1
2019-02-15 Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaNordic SME Sweden
SektorHälsovård
IndustriMedicinteknik
Lumito specialiserar sig på medicinsk teknik för digital patologi. Bolaget strävar efter att förbättra vävnadsdiagnostiken med sin patenterade teknologi baserad på uppkonverterade nanopartiklar. Bolaget planerar att initialt lansera sin första produkt för forskningslaboratorier. Bolaget bildades under 2010 som en spinoff från en forskargrupp vid Lunds universitets avdelning för atomfysik och lasercentrum. Lumito har sitt huvudkontor i Lund.
First factory produced SCIZYS reagent kit is now available
2023-10-17 10:00:00

The first batch of Lumito's reagent intended for end customer sales is now produced by Lumito's production partner, Uniogen Oy.

Lumito has collaborated with Uniogen Oy (formerly Kaivogen Oy) for over 15 months to prepare the production of the nanoparticle-based reagent kit belonging to the company's digital pathology solution.

- It feels great that a crucial ingredient in our solution now is produced so that we are completely ready when the next piece of the puzzle comes into place and then be able to launch SCIZYS, comments Mattias Lundin, Lumitos CEO.

SCIZYS Erbium Kit forms an essential part of the company's first product, which also consists of a digital scanner.

For further information, please contact:

Mattias Lundin, CEO Lumito
E-mail: ml@lumito.se
Ph: +46 76 868 45 09 

Lumito

Lumito specialises in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalised healthcare. The technology enables higher-contrast images without irrelevant background information, making it easier for pathologists to find cancer indications. The technology, based on Up Converting NanoParticles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shortened analysis times. The method has several potential applications, but Lumito has focused primarily on digital pathology and first on a release of SCIZYS by Lumito for use in research laboratories. The company is a spin-off of a research group at the Department of Atomic Physics and Laser Centre. www.lumito.se/en

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

Image Attachments
SCIZYS Erbium Kit

Attachments
First factory produced SCIZYS reagent kit is now available

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden